RxDoctor Payments Data

Hani Alkhatib, MD

Interventional Cardiology · Baltimore, MDNPI 1699116491

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (47.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 55.1% of the total. Reporting peaked in 2019 at $11,031 and has fallen 64.0% since, to $3,976 in 2025.

$18,943in general payments, 2019–2025

Across 117 payments — averaging $161.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Boston Scientific$4K
  • Angiodynamics, Inc.$2K
  • Edwards Lifesciences$2K
  • Abbott$325
  • E.r. Squibb & Sons, L.L.C.$181
  • plus $479 from 9 others

What the payments were for

  • Grants$9,00048%
  • Travel & lodging$4,12322%
  • Food & beverage$5,82031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,943 in reported general payments places this provider in the 70th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$325,304
Medicare patients
1,446
Services billed
3,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$112,734
FarxigaDapagliflozin Propanediol61$55,562
EntrestoSacubitril/Valsartan44$50,909
XareltoRivaroxaban31$31,351
JardianceEmpagliflozin24$27,757
Metoprolol Succinate130$2,619
Rosuvastatin Calcium35$1,372
Atorvastatin Calcium95$1,162
ClopidogrelClopidogrel Bisulfate90$930
Torsemide24$897
Amiodarone Hcl14$735
Potassium Chloride19$603
Carvedilol43$561
Nitroglycerin22$503
Losartan Potassium41$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$112,734101 claims
AstraZenecaFarxiga$67$55,56261 claims
NovartisEntresto$47$50,90944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 71 interventional cardiology providers in Maryland.

Other interventional cardiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →